2 edition of Bone marrow micrometastases and metalloproteinase expression in primary breast cancer found in the catalog.
Bone marrow micrometastases and metalloproteinase expression in primary breast cancer
Martin Stuart Wadley
Thesis (M.D.) - University of Birmingham, Department of Surgery, Faculty of Medicine and Dentistry.
|Statement||by Martin Stuart Wadley.|
|The Physical Object|
|Pagination||iv, 251 p. :|
|Number of Pages||251|
Matrix metalloproteinase-2 (MMP-2) is important in the dissemination and invasion of tumor cells and activates angiogenesis. We present an immunocytochemical study of MMP-2 expression in circulating prostate cells (CPCs), disseminated tumor cells (DTCs), and micrometastasis (mM) in bone marrow of men with prostate Dormant estrogen receptor positive (ER+) breast cancer micrometastases in the bone marrow survive adjuvant chemotherapy and recur stochastically for more than 20 years. We hypothesized that inflammatory cytokines produced by stromal injury can re-awaken dormant breast cancer cells. We used an established in vitro dormancy model of Michigan Cancer Foundation-7 (MCF-7) breast cancer A pooled analysis of bone marrow micrometastasis in breast cancer. (). Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. (). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and TPS Background: Bone marrow (BM) micrometastases confer a poor prognosis to early-stage breast cancer (BC) and HER-2/neu(+) BC is a high-risk phenotype. We have shown that BM-associated stromal cells support the survival of metastatic BC in microenvironmental niches and this activity is dependent on VEGF and CXCL Therefore, the growth of nascent tumor cell clusters in
The humble petition of the Lord Mayor, Aldermen, and Commons of the city of London in Common Council assembled
The man who wasnt Maigret
Home for Christmas
Mathematical enterprises for schools.
Mining Commissioners cases, Ontario, 1969-1979. by Grant H. Ferguson
Distribution of initial student payment summary (SPS) for the 1989-90 award year.
Providing for the consideration of H.R. 1141, the 1999 Emergency Supplemental Appropriations Act
Collapse of Enron
Number rhymes and finger plays
Rye and Romney Marsh
In peril on the sea
Flexible manufacture of lightweight frame structures
Among the mechanisms of breast cancer cell dissemination to the BM, bone and bone marrow homing of cancer cells may depend on similar molecular determinants, especially the SDF1/CXCR4 axis.
47 48 CXCR4 is a G protein-coupled Bone marrow micrometastases and metalloproteinase expression in primary breast cancer book, 49 which plays a role in the chemotaxis of breast cancer :// Matrix metalloproteinase-2 (MMP-2) is important in the dissemination and invasion of tumor cells and activates angiogenesis.
We present an immunocytochemical study of MMP-2 expression in circulating prostate cells (CPCs), disseminated tumor cells (DTCs), and micrometastasis (mM) in bone marrow of men with prostate cancer.
Methods and :// Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin. Cancer Res. 11, – Bone Marrow Micrometastases in Breast Cancer Article (PDF Available) in New England Journal of Medicine (20); author reply December with 19 Reads How we measure 'reads' /_Bone_Marrow_Micrometastases_in_Breast_Cancer.
Among the women without lymph-node metastases, 14 of the with bone marrow micrometastases died of cancer-related causes, as did 2 of the without bone marrow micrometastases (P Bone Marrow and Peripheral Blood.
In breast cancer, the bone marrow is the single most common site of metastasis, and 80% of patients with recurrent tumors develop bone marrow metastases at some point during the evolution of their disease. Immunohistochemistry can show the presence of occult metastases in the bone marrow in approximately 10 Matrix metalloproteinase-2 (MMP-2) expression in primary prostate cancer is associated with a worse prognosis [10–12].
MMP-2 Bone marrow micrometastases and metalloproteinase expression in primary breast cancer book thought to be important in the dissemination and invasion of cancer cells [13, 14] and through the activation of MMP-9 thought to activate angiogenesis and thus permits tumor growthand the formation of :// Introduction.
HER-2 has been associated with castrate resistant prostate cancer and matrix metalloproteinase-2 (MMP-2) in the dissemination and invasion of tumor cells as well as activating angiogenesis.
We present an immunocytochemical study of the effect of androgen blockade on the Bone marrow micrometastases and metalloproteinase expression in primary breast cancer book of HER-2 and MMP-2 in bone marrow micrometastasis and the surrounding stromal cells Hsu CP, Shen GH, Ko JL.
Matrix metalloproteinase expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer. Lung Cancer [Internet] ; 52 (3)– [Google Scholar] This book provides, all in one resource, the most recent data on bone cancer development (cellular and molecular mechanisms), genomic and proteomic analyses, clinical analyses (histopathology, imaging, pain monitoring), as well as new therapeutic approaches and clinical trials for primary bone tumors Bone marrow micrometastases and metalloproteinase expression in primary breast cancer book bone :// The cellular and molecular mechanisms by which a tumour cell undergoes metastasis to a predetermined location are largely unknown.
Here we demonstrate that bone marrow-derived haematopoietic progenitor cells that express vascular endothelial growth factor receptor 1 (VEGFR1; also known as Flt1) home to tumour-specific pre-metastatic sites and form cellular clusters before the A.
Berg, A. Berner, W. Lilleby, et of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy Int J Cancer Bone is the most common site of metastatic breast cancer and accounts for about 70% of metastases.
11 It is frequently associated with osteolytic type metastatic lesions due to hyperactive Of patients with prostate cancer who have had a radical prostatectomy, 72% have DTCs in the bone marrow ; and 30% of patients with localized breast cancer have bone marrow Disseminated tumor cells (DTCs) found in the bone marrow (BM) of patients with breast cancer portend a poor prognosis and are thought to be intermediaries in the metastatic process.
To assess the clinical relevance of a mouse model for identifying possible prognostic and predictive biomarkers of these cells, we have employed patient-derived xenografts (PDX) for propagating and Precise staging of non–small-cell lung cancer (NSCLC) determines prognosis and promotes important decisions regarding treatment options.
Previous staging system such as the tumor-node-metastasis staging system had limitations in the range in survival rates. However, the new staging system has limitations too. For example, after obvious complete resection in patients with stage I disease Hypoxia & breast cancer.
Worldwide, breast cancer is the most common cancer in women. Upon diagnosis, the patients treatment options are determined by the presence or absence of three key receptors; ER, PR and HER2, as well as clinical staging based Micrometastases can often be detected in bone marrow aspirates in patients that have no radiological or nuclear medicine evidence of disease following surgery for the primary tumor.
These micrometastases are thought to be the basis for the metastases that will subsequently occur in understaged patients. Injection of tumor cells into the left Early dissemination of cancer cells from the primary tumor via the circulatory system may result in the formation of microscopic metastatic deposits (micrometastases, MMs) in secondary compartments such as the bone marrow (BM), where there is a favorable environment for Mansi JL, Berger U, Easton D et al.
Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Med. ; – CrossRef Google Scholar Cyclooxygenase-2 expression in primary human colorectal cancers and bone marrow micrometastases Article in Digestive and Liver Disease 36(6) June with 2 Reads How we measure 'reads' In book: Breast Disease and they are also considered micrometastases in the bone marrow.
The morphological characteristics of DTCs include large cells with a large nucleus, nuclear granulation "Lymph node and bone marrow micrometastases define the prognosis of patients with pN0 oesophageal cancer" by Karstens et al provides a systematic study of the clinical significance of bone marrow micrometastases in oesophageal cancer.
The manuscript is very well written and provides excellent background and context for understanding the :// Methods Between andbone marrow aspirates were obtained from patients at the time of surgery for primary invasive breast cancer.
DTCs in bone marrow were identified using monoclonal Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation.
Cancer. ;– CrossRef PubMed Google Scholar To our knowledge, there are only a few studies regarding EMMPRIN expression in disseminated tumor cells from bone marrow, and these cells potentially reflect minimal residual disease. Disseminated tumor cells can be identified in high percentages of patients, even those with early stage, solid cancers, such as breast, colon, or gastric Purpose: EMMPRIN (extracellular matrix metalloprotease inducer) is a glycosylated member of the immunoglobulin superfamily known to stimulate the production of matrix metalloproteases (MMPs) 1, 2, and 3 and MT1-MMP in peritumoral fibroblasts.
We here evaluated whether EMMPRIN expression is related to tumor progression in human breast :// Bone is the most common metastatic site for breast cancer, and bone metastases develop in 65–75% of patients with metastatic breast cancer.
1 These metastases can result in substantial morbidity Disseminated tumor cells in bone marrow of gastric cancer patients: correlation with tumor hypoxia and clinical relevance.
Larissa Bubnovskaya R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Bone marrow and peripheral blood samples from gastric cancer patients.
Aspiration of both bone marrow and peripheral blood was conducted under general anaesthesia immediately before surgery as One in four breast cancer patients is at risk of developing bone metastases in her life time.
The early prevention of bone metastases is a crucial challenge. It has been suggested that the use of zoledronic acid (ZOL) in the adjuvant setting may reduce the persistence of disseminated tumor cells and thereby might improve outcome, specifically in a population of patients with a low estrogen Most breast cancer patients die due to metastases, and the early onset of this multistep process is usually missed by current tumor staging modalities.
Therefore, ultrasensitive techniques have been developed to enable the enrichment, detection, isolation and characterization of disseminated tumor cells in bone marrow and circulating tumor cells in the peripheral blood of cancer :// Purpose: Pathologic angiogenesis has been correlated with tumor growth, dissemination, metastasis, and prognosis in solid tumors including breast cancer.
Angiogenesis has also been implicated in the pathophysiology of, and shown to be a therapeutic target in tumors arising in the bone marrow. The status of angiogenesis in the bone marrow of breast cancer patients is :// It is widely accepted that metastasis is a late event in cancer progression.
Here, however, we show that tumor cells can disseminate systemically from earliest epithelial alterations in HER-2 and PyMT transgenic mice and from ductal carcinoma in situ in women. Wild-type mice transplanted with single premalignant HER-2 transgenic glands displayed disseminated tumor cells and micrometastasis in (07) Figure 1 Steps of Bone Metastasis.
Bone metastasis is a multiple step and lengthy process. Facilitated by the epithelial–mesenchymal transition and the primary tumor microenvironment (e.g., hypoxia and cancer-associated fibroblasts), invasive tumor cells may intravasate into the blood vessel as single circulating tumor cells (CTCs) or CTC ://(18) CK-positive cells in bone marrow carry characteristics exclusively known for tumor cells, such as HER2 amplification and protein overexpression, 7,8 as well as genomic changes that are identical to those of the respective primary tumor.
9 We recently showed for the first time that HER2 expression on bone marrow micrometastases is associated Purpose: The detection of disseminated occult breast cancer cells in peripheral blood and bone marrow is associated with poor prognosis.
Since a high proportion of these cells express the HER-2 receptor, we evaluated the effectiveness of the anti-HER-2 antibody trastuzumab (Herceptin) administration to eliminate them. Experimental Design: Thirty patients with prior chemotherapy The bone and bone marrow are the most common sites of metastasis in breast cancer.
Matrix metalloproteinases (MMPs), particularly MMP-2, produced by cancer cells or, more typically, induced in the adjacent normal stroma are necessary for the degradation of extracellular matrix essential for cancer metastasis. Here we describe a mechanism by which breast cancer cells can rapidly use MMP-2 Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CHRM, Gastroph S, Trimpl A, Wischnik A, Dimpfl Th.
Kindermann G, Riethmüller G, Schlimok G () Cytokeratin-positive bone marrow micrometastases and survival of breast cancer patients with stage I-III disease. N Engl J Med – PubMed Google Scholar Gebhardt F, Zanker KS, Brandt B () Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micrometastases from breast cancer patients.
Biochem Biophys Res Commun – PubMed CrossRef Google Scholar. Purpose: Pdf aim of the study was to explore the pdf of analyzing bone marrow (BM) for the presence of isolated tumor cell(s) (ITCs) in disease-free breast cancer patients 3 years after diagnosis.
Experimental Design: ITCs in BM at operation was found to be an independent prognostic factor in breast cancer patients. Among these, disease-free patients were analyzed with a CK-positive cells in bone marrow carry characteristics exclusively known for tumor cells, such download pdf HER2 amplification and protein overexpression, 7,8 as well as genomic changes that are identical to those of the respective primary tumor.
9 We recently showed for the first time that HER2 expression on bone marrow micrometastases is associated Abstract. The presence ebook circulating tumor cells (CTCs) in the blood as well as disseminated tumor cells (DTCs) in the bone marrow of breast cancer patients is associated with a worsened prognosis in the primary as well as in the metastatic ://